Swiss National Bank
BPMC

Swiss National Bank’s Blueprint Medicines BPMC Stock Holding History

Swiss National Bank’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-122,000
Closed -$15.6M – 2324
2025
Q2 		$15.6M Sell
122,000
-1,100
-0.9% -$114K 0.01% 708
2025
Q1 		$10.9M Sell
123,100
-1,500
-1% -$146K 0.01% 855
2024
Q4 		$10.9M Buy
124,600
+8,400
+7% +$769K 0.01% 900
2024
Q3 		$10.7M Buy
116,200
+1,800
+2% +$179K 0.01% 902
2024
Q2 		$12.3M Buy
114,400
+400
+0.4% +$40K 0.01% 797
2024
Q1 		$10.8M Buy
114,000
+500
+0.4% +$42.9K 0.01% 877
2023
Q4 		$10.5M Sell
113,500
-19,400
-15% -$1.26M 0.01% 862
2023
Q3 		$6.67M Buy
132,900
+2,300
+2% +$123K 0.01% 1106
2023
Q2 		$8.25M Buy
130,600
+1,500
+1% +$81.5K 0.01% 1016
2023
Q1 		$5.81M Sell
129,100
-15,100
-10% -$680K ﹤0.01% 1161
2022
Q4 		$6.32M Buy
144,200
+2,900
+2% +$139K ﹤0.01% 1178
2022
Q3 		$9.31M Buy
141,300
+1,800
+1% +$116K 0.01% 916
2022
Q2 		$7.05M Buy
139,500
+7,400
+6% +$433K ﹤0.01% 1106
2022
Q1 		$8.44M Buy
132,100
+9,600
+8% +$689K ﹤0.01% 1109
2021
Q4 		$13.1M Hold
122,500
– – 0.01% 858
2021
Q3 		$12.6M Buy
122,500
+1,100
+0.9% +$102K 0.01% 882
2021
Q2 		$10.7M Buy
121,400
+400
+0.3% +$36.7K 0.01% 987
2021
Q1 		$11.8M Buy
121,000
+2,300
+2% +$230K 0.01% 904
2020
Q4 		$13.3M Buy
118,700
+2,000
+2% +$211K 0.01% 792
2020
Q3 		$10.8M Buy
116,700
+2,100
+2% +$162K 0.01% 778
2020
Q2 		$8.94M Buy
114,600
+23,900
+26% +$1.62M 0.01% 823
2020
Q1 		$5.3M Buy
90,700
+1,400
+2% +$90.1K 0.01% 904
2019
Q4 		$7.15M Buy
89,300
+1,900
+2% +$142K 0.01% 940
2019
Q3 		$6.42M Buy
87,400
+9,400
+12% +$813K 0.01% 957
2019
Q2 		$7.36M Buy
78,000
+4,900
+7% +$404K 0.01% 900
2019
Q1 		$5.85M Buy
73,100
+3,300
+5% +$244K 0.01% 991
2018
Q4 		$3.76M Buy
69,800
+1,300
+2% +$79K ﹤0.01% 1151
2018
Q3 		$5.35M Hold
68,500
– – 0.01% 1070
2018
Q2 		$4.35M Buy
68,500
+1,300
+2% +$103K 0.01% 1201
2018
Q1 		$6.16M Buy
67,200
+2,500
+4% +$215K 0.01% 928
2017
Q4 		$4.88M Buy
64,700
+13,500
+26% +$950K 0.01% 1076
2017
Q3 		$3.57M Hold
51,200
– – ﹤0.01% 1244
2017
Q2 		$2.59M Buy
51,200
+4,900
+11% +$208K ﹤0.01% 1416
2017
Q1 		$1.85M Buy
46,300
+5,000
+12% +$179K ﹤0.01% 1617
2016
Q4 		$1.16M Buy
41,300
+11,100
+37% +$335K ﹤0.01% 1936
2016
Q3 		$897K Hold
30,200
– – ﹤0.01% 2037
2016
Q2 		$612K Hold
30,200
– – ﹤0.01% 2244
2016
Q1 		$527K Buy
30,200
+16,000
+113% +$278K ﹤0.01% 2276
2015
Q4 		$374K Buy
+14,200
New +$320K ﹤0.01% 2398

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Swiss National Bank's BPMC Position: Q3 2025 in Review

Swiss National Bank sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 122,000 shares — an estimated $15.6M sold.

Swiss National Bank first reported a position in BPMC in Q4 2015 and held it in 39 quarters. The position peaked at $15.6M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Swiss National Bank reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Swiss National Bank sold 122,000 Blueprint Medicines shares in Q3 2025, an estimated $15.6M.
  • Swiss National Bank first reported a position in Blueprint Medicines in Q4 2015 and held it in 39 quarters.
  • Swiss National Bank's Blueprint Medicines position peaked at $15.6M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Swiss National Bank's 13F filing for Q3 2025, filed 13 Nov 2025.